DossierNicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome
References (16)
Gum chewing as therapy for Tourette syndrome
Pediatr. Neurol
(1988)Hemidystonia relieved by nicotine
Lancet
(1984)- et al.
Nicotine gum and haloperidol in Tourette's syndrome
Lancet
(1988) Can nicotine control panic attacks ?
Am. J. Psychiatry
(1985)Nicotine: a unique psychoactive drug—arousal with skeletal muscle relaxation
Psychopharmacol. Bull.
(1986)- et al.
Goodman and Gilman's: The Pharmacological Basis of Therapeutics
(1985) - et al.
Normative data on revised Conner's parent and teacher rating scales
J. Abnorm. Child Psychol.
(1978) - et al.
Long-term cis-flupenthixol administration produces cerebral dopamine receptor supersensitivity and increases striatal acetylcholine levels
Br. J. Pharmacol.
(1981)
Cited by (65)
Nicotinic acetylcholine receptors in neurological and psychiatric diseases
2023, Pharmacological ResearchThe boundlessness of behavioral neuroscience: A look across 30 years
2022, Neuroscience and Biobehavioral ReviewsRole for the nicotinic cholinergic system in movement disorders; Therapeutic implications
2014, Pharmacology and TherapeuticsCitation Excerpt :However, currently available drugs are only partially effective and associated with side effects and thus new therapies are constantly being sought. Initial open label studies with the nicotine gum showed a substantial decrease in tics and improvement of concentration/attention span in Tourette's syndrome patients treated with haloperidol, although nicotine alone appeared to have little effect (Sanberg et al., 1989; McConville et al., 1991). However, side effects, such as nausea and bitter taste limited the usefulness of the nicotine gum.
Clinical pharmacology of nondopaminergic drugs in tourette syndrome
2013, International Review of NeurobiologyCitation Excerpt :With regard to its antipsychotic potentiating effects (see below), the mechanism(s) of action remain unclear. In 1989, Sanberg et al. reported that nicotine potentiates haloperidol-induced hypokinesia in rats and went on to treat 10 GTS nonadult patients with 2 mg nicotine gums as adjunct to ongoing haloperidol treatment (Sanberg et al., 1989). Improvement was noted in 80% of children treated, but the vast majority discontinued the nicotine gum because of side effects (bitter taste and nausea).
Individual phenotype predicts nicotine-haloperidol interaction in catalepsy: Possible implication for the therapeutic efficacy of nicotine in Tourette's syndrome
2013, Behavioural Brain ResearchCitation Excerpt :This effect of haloperidol is mediated via blockade of striatal dopamine D2 receptors [7]. Interestingly, nicotine can potentiate haloperidol-induced catalepsy while not having any effect on its own [8,9]. This finding is somewhat surprising given that nicotine, a psychostimulant, increases locomotion via stimulation of midbrain dopamine cells [10].
Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette's, depression, and beyond
2012, Physiology and BehaviorCitation Excerpt :One piece of nicotine gum (2 mg) was given to each child three times a day. The study found that 80% of the children showed an improvement in their symptoms while chewing the gum, but 70% of the participants discontinued the gum use due to its side-effects (mainly bitter taste and stomach aches) [24]. A follow-up study was conducted with an additional 10 TS patients, eight children and two adults with a mean age of 18.7 years, who were receiving treatment with haloperidol [25].